Joseph J. Sacco

Liverpool, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 63 publications

Phase 1/2 study of IMC-C103C, a T cell receptor bispecific (MAGE-A4×CD3) ImmTAC targeting MAGE-A4-expressing malignancies.

Phase 1/2 study of IMC-C103C, a T cell receptor bispecific (MAGE-A4×CD3) ImmTAC targeting MAGE-A4-expressing malignancies.

Journal: Journal for immunotherapy of cancer

Published: July 07, 2026

Meeting Report From the 2025 Cure Ocular Melanoma (CURE OM) Global Science Meeting, Amsterdam, the Netherlands, October 2025.

Meeting Report From the 2025 Cure Ocular Melanoma (CURE OM) Global Science Meeting, Amsterdam, the Netherlands, October 2025.

Journal: Pigment cell & melanoma research

Published: April 13, 2026

Five-year survival with tebentafusp in metastatic uveal melanoma.

Five-year survival with tebentafusp in metastatic uveal melanoma.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: March 02, 2026

Real-world efficacy and toxicity of tebentafusp in metastatic uveal melanoma patients treated on the United Kingdom expanded access programme.

Real-world efficacy and toxicity of tebentafusp in metastatic uveal melanoma patients treated on the United Kingdom expanded access programme.

Journal: The oncologist

Published: February 27, 2026

Biodistribution, shedding, and transmissibility of vusolimogene oderparepvec (RP1).

Biodistribution, shedding, and transmissibility of vusolimogene oderparepvec (RP1).

Journal: Frontiers in oncology

Published: January 28, 2026

Uveal melanoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up.

Uveal melanoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up.

Journal: ESMO open

Published: September 24, 2025

Characteristics and Outcomes of Patients with Early or Late Uveal Melanoma Metastasis: A Review.

Characteristics and Outcomes of Patients with Early or Late Uveal Melanoma Metastasis: A Review.

Journal: Ocular oncology and pathology

Published: September 14, 2025

RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE).

RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 08, 2025

Methodology for generating chorioallantoic membrane patient-derived xenograft (CAM-PDX) models of pleural mesothelioma and performing preclinical imaging for the translation of cancer studies and drug screening.

Methodology for generating chorioallantoic membrane patient-derived xenograft (CAM-PDX) models of pleural mesothelioma and performing preclinical imaging for the translation of cancer studies and drug screening.

Journal: F1000Research

Published: June 26, 2025

Uveal Melanoma UK national guidelines: 2023 update.

Uveal Melanoma UK national guidelines: 2023 update.

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 11, 2025

Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients.

Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: May 12, 2025

An Open-label, Randomized Study of Melphalan/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal Melanoma.

An Open-label, Randomized Study of Melphalan/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal Melanoma.

Journal: Annals of surgical oncology

Published: January 02, 2025

Showing 1-12 of 63

Last Updated: 09/26/2026